Medexus Pharmaceuticals Inc (MDP)

Currency in CAD
5.43
-0.26(-4.57%)
Closed·
MDP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.375.69
52 wk Range
2.515.72
Key Statistics
Prev. Close
5.43
Open
5.69
Day's Range
5.37-5.69
52 wk Range
2.51-5.72
Volume
59.15K
Average Volume (3m)
39.1K
1-Year Change
101.1111%
Book Value / Share
2.20
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.64
Upside
+40.70%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.64
(+40.70% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy7.00+28.91%6.75Maintain12/11/2026
Canaccord
Buy6.50+19.71%6.00Maintain29/06/2026
Canaccord
Buy6.00+10.50%-New Coverage26/05/2026

Medexus Pharmaceuticals Inc Earnings Call Summary for Q2/2027

  • Medexus Q2 FY2027 revenue rose 17.8% YoY to $29.1M, driven by GRAFAPEX and IXINITY; net income turned positive at $0.8M vs. $0.3M loss.
  • GRAFAPEX generated $5.7M in revenue with 156% YoY demand growth; company guides $30-32M annual revenue for FY2027, targeting acceleration post-ASH.
  • Operating cash flow surged 63.6% to $5.4M; adjusted EBITDA increased 15.9% to $5.1M despite adjusted gross margin compression to 64.0%.
  • Management expects GRAFAPEX adoption to accelerate following December ASH conference presentations; long-term target of $100-175M annual revenue maintained.
  • Shares rose 2.51% to $5.31, near 52-week high; net debt-to-EBITDA improved to 0.97x with UM171 Canadian launch expected between 2028-2031.
Last Updated: 13/11/2026, 12:40 am
Read Full Transcript

Earnings

Latest Release
12/11/2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
24.74M / 43.02M
EPS Revisions
Last 90 days

MDP Income Statement

Compare MDP to Peers and Sector

Metrics to compare
MDP
Peers
Sector
Relationship
P/E Ratio
−96.6x−1.0x−0.2x
PEG Ratio
0.24−0.010.00
Price/Book
2.5x0.8x2.6x
Price / LTM Sales
1.1x1.4x2.8x
Upside (Analyst Target)
40.7%80.5%65.0%
Fair Value Upside
Unlock0.8%9.5%Unlock

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Employees
90
Market
Canada

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.05M3.35%5.72M
Other Institutional Investors
1.67K0.01%9.05K
Public Companies & Retail Investors
30.37M96.64%164.92M
Total
31.43M100.00%170.64M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Arrow Capital Management Inc.2.52%791,6004,298
Exemplar Growth and Income Fund2.52%791,6004,298

FAQ

What Is the Medexus (MDP) Stock Price Today?

The Medexus stock price today is 5.43 CAD.

What Stock Exchange Does Medexus Trade On?

Medexus is listed and trades on the Toronto Stock Exchange.

What Is the Stock Symbol for Medexus?

The stock symbol for Medexus is "MDP."

What Is the Medexus Market Cap?

As of today, Medexus market cap is 170.64M CAD.

What Is Medexus's Earnings Per Share (TTM)?

The Medexus EPS (TTM) is -0.055.

From a Technical Analysis Perspective, Is MDP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Medexus Stock Split?

Medexus has split 2 times.

How Many Employees Does Medexus Have?

Medexus has 90 employees.

What is the current trading status of Medexus (MDP)?

As of 16/11/2026, Medexus (MDP) is trading at a price of 5.43 CAD, with a previous close of 5.43 CAD. The stock has fluctuated within a day range of 5.37 CAD to 5.69 CAD, while its 52-week range spans from 2.51 CAD to 5.72 CAD.

What Is Medexus (MDP) Price Target According to Analysts?

The average 12-month price target for Medexus is 7.64 CAD, with a high estimate of 9 CAD and a low estimate of 6.5 CAD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +40.70% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.